RAPS and National University of Singapore Launch Regulatory Affairs Graduate Certificate Program - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
RAPS and National University of Singapore Launch Regulatory Affairs Graduate Certificate Program

Source: Company News Release

The Regulatory Affairs Professionals Society (RAPS) and the National University of Singapore (NUS) have announced the official launch of their joint Graduate Certificate in Medical Devices Regulatory Affairs (MDRA) program. The program is intended for Singapore-based regulatory professionals, and was developed in partnership with the government of Singapore to cultivate an industry-ready regulatory workforce.

“Singapore has become an important center for biomedical research and business today,” said RAPS Executive Director Sherry Keramidas, PhD, FASAE, CAE. “This program will be the first to offer instruction specifically designed to develop the medical device regulatory knowledge that is in high demand by the global companies located there.”

The MDRA program builds the foundational knowledge, critical thinking and application skills required of regulatory professionals. The curriculum will be delivered through a combination of online training, interactive seminars, peer interaction and case-based learning, and will cover regulations of ASEAN nations, China, the Asia-Pacific region, the US and Europe.

The program draws on the teaching and research excellence of NUS’ biomedical engineering faculty and the real world expertise of RAPS’ renowned regulatory leaders from around the world.

Enrollment is open from now until 8 August. Visit www.bioeng.nus.edu.sg/edu/mdra.html for full program details and application information, or contact the RAPS Pan-Asia office at RAPSAsia@raps.org or Tel: +65 6496 5507.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Company News Release,
Click here